Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

TA226 Lymphoma (follicular non-Hodgkin's) - rituximab: review decision - August 2014 information

TA226 Lymphoma (follicular non-Hodgkin's) - rituximab: review decision- August 2014: appendix a decision paper presented to the Institute's Guidance Executive (PDF 107 KB)

TA226 Lymphoma (follicular non-Hodgkin's) - rituximab: review proposal - June 2014 information

Appendix A: matrix of stakeholders (PDF 99 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 444 KB)

Lymphoma (follicular non-Hodgkin's) - rituximab: equality impact assessment (PDF 16 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: final appraisal determination  information

Lymphoma (follicular non-Hodgkin's ) - rituximab: final appraisal determination document (PDF 275 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 1.5 MB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: consultee and commentator comments on the ACD

Lymphoma (follicular non-Hodgkin's ) - rituximab: Roche (PDF 235 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: Lymphoma Association, Leukaemia CARE and Leukaemia & Lymphoma Research (PDF 121 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: National Cancer Research Institute, Royal College of Physicians, Royal College of Radiologists, Association of Clinical Pathologists and Joint Collegiate Council for Oncology (PDF 112 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: Royal College of Nursing (PDF 59 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: Royal College of Pathologists and the British Society for Haematology (PDF 131 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: Department of Health (PDF 68 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: comments on the ACD received from the public through the NICE website (PDF 67 KB)

Lymphoma (follicular non-Hodgkin's ) - rituximab: ERG critique of extra information submitted by Roche (PDF 659 KB)

Follicular non-Hodgkin's lymphoma - rituximab: appraisal consultation 2

Follicular non-Hodgkin's lymphoma - rituximab: appraisal consultation document information

Follicular non-Hodgkin's lymphoma - rituximab: comments on the Appraisal Consultation Document received through the NICE website

Follicular non-Hodgkin's lymphoma - rituximab: submission from Roche (PDF 192 KB)

Follicular non-Hodgkin's lymphoma - rituximab: submission from Royal College of Nursing (PDF 59 KB)

Follicular non-Hodgkin's lymphoma - rituximab: submission from Department of Health (PDF 68 KB)

Follicular non-Hodgkin's lymphoma - rituximab: submission from NHS Camden (PDF 119 KB)

Follicular non-Hodgkin's lymphoma - rituximab: submission from Welsh Assembly Government (PDF 47 KB)

Follicular non-Hodgkin's lymphoma - rituximab: submission from Commissioning Support Appraisal Service (PDF 549 KB)

Follicular non-Hodgkin's lymphoma - rituximab: submission from Liverpool Reviews and Implementation Group (LRIG) (PDF 131 KB)

Follicular non-Hodgkin's lymphoma - rituximab: expert personal statement - Dr Robert Marcus (PDF 44 KB)

Follicular non-Hodgkin's lymphoma - rituximab: comments on the ACD received from the public through the NICE website (PDF 45 KB)

Follicular non-Hodgkin's lymphoma - rituximab: appraisal consultation

Follicular non-Hodgkin's lymphoma - rituximab: appraisal consultation document information

Follicular non-Hodgkin's lymphoma - rituximab: evaluation report

Follicular non-Hodgkin's lymphoma - rituximab: pre-meeting briefing (PDF 231 KB)

Follicular non-Hodgkin's lymphoma - rituximab: Evidence Review Group report (PDF 811 KB)

Follicular non-Hodgkin's lymphoma - rituximab: non-manufacturer submissions

Follicular non-Hodgkin's lymphoma - rituximab: Leukaemia CARE (PDF 56 KB)

Follicular non-Hodgkin's lymphoma - rituximab: Lymphoma Association (PDF 213 KB)

Follicular non-Hodgkin's lymphoma - rituximab: Cancer Network Pharmacists Forum (PDF 82 KB)

Follicular non-Hodgkin's lymphoma - rituximab: Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO (PDF 56 KB)

Follicular non-Hodgkin's lymphoma - rituximab: manufacturer submission

Follicular non-Hodgkin's lymphoma - rituximab: Roche (PDF 2.53 MB)

Follicular non-Hodgkin's lymphoma - rituximab: NICE request to the manufacturer for clarification on their submission (PDF 49 KB)

Follicular non-Hodgkin's lymphoma - rituximab: manufacturer's response to NICE's request for clarification (PDF 554 KB)

Follicular non-Hodgkin's lymphoma - rituximab: manufacturer's response to further clarification questions (PDF 121 KB)

Follicular non-Hodgkin's lymphoma - rituximab: expert written personal statements

Follicular non-Hodgkin's lymphoma - rituximab: Johnson (PDF 75 KB)

Follicular non-Hodgkin's lymphoma - rituximab: McCarthy (PDF 58 KB)

Follicular non-Hodgkin's lymphoma - rituximab: Marcus (PDF 236 KB)

Follicular non-Hodgkin's lymphoma - rituximab: Nelson (PDF 31 KB)

Follicular non-Hodgkin's lymphoma - rituximab: final scope (PDF 29 KB)

Follicular non-Hodgkin's lymphoma - rituximab: final matrix (PDF 35 KB)

Follicular non-Hodgkin's lymphoma - rituximab: comments on the matrix (PDF 28 KB)

Follicular non-Hodgkin's lymphoma - rituximab: comments on the scope (PDF 113 KB)